Your browser doesn't support javascript.
loading
Comparison of two T-cell assays to evaluate T-cell responses to SARS-CoV-2 following vaccination in naïve and convalescent healthcare workers.
Phillips, Eloise; Adele, Sandra; Malone, Tom; Deeks, Alexandra; Stafford, Lizzie; Dobson, Susan L; Amini, Ali; Skelly, Donal; Eyre, David; Jeffery, Katie; Conlon, Christopher P; Dold, Christina; Otter, Ashley; D'Arcangelo, Silvia; Turtle, Lance; Klenerman, Paul; Barnes, Eleanor; Dunachie, Susanna J.
Afiliación
  • Phillips E; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Adele S; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Malone T; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Deeks A; Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Stafford L; Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Dobson SL; Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Amini A; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK.
  • Skelly D; Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Eyre D; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
  • Jeffery K; Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Conlon CP; Nuffield Department of Clinical Neuroscience, University of Oxford, UK.
  • Dold C; Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Otter A; Big Data Institute, University of Oxford, Oxford, UK.
  • D'Arcangelo S; Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Turtle L; Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Klenerman P; Oxford Centre for Global Health Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
  • Barnes E; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Dunachie SJ; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Clin Exp Immunol ; 209(1): 90-98, 2022 07 22.
Article en En | MEDLINE | ID: mdl-35522978
T-cell responses to SARS-CoV-2 following infection and vaccination are less characterized than antibody responses, due to a more complex experimental pathway. We measured T-cell responses in 108 healthcare workers (HCWs) using the commercialized Oxford Immunotec T-SPOT Discovery SARS-CoV-2 assay service (OI T-SPOT) and the PITCH ELISpot protocol established for academic research settings. Both assays detected T-cell responses to SARS-CoV-2 spike, membrane, and nucleocapsid proteins. Responses were significantly lower when reported by OI T-SPOT than by PITCH ELISpot. Four weeks after two doses of either Pfizer/BioNTech BNT162b or ChAdOx1 nCoV-19 AZD1222 vaccine, the responder rate was 63% for OI T-SPOT Panels 1 + 2 (peptides representing SARS-CoV-2 spike protein excluding regions present in seasonal coronaviruses), 69% for OI T-SPOT Panel 14 (peptides representing the entire SARS-CoV-2 spike), and 94% for the PITCH ELISpot total spike. The two OI T-SPOT panels correlated strongly with each other showing that either readout quantifies spike-specific T-cell responses, although the correlation between the OI T-SPOT panels and the PITCH ELISpot total spike was moderate. The standardization, relative scalability, and longer interval between blood acquisition and processing are advantages of the commercial OI T-SPOT assay. However, the OI T-SPOT assay measures T-cell responses at a significantly lower magnitude compared to the PITCH ELISpot assay, detecting T-cell responses in a lower proportion of vaccinees. This has implications for the reporting of low-level T-cell responses that may be observed in patient populations and for the assessment of T-cell durability after vaccination.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / COVID-19 / Vacuna BNT162 / ChAdOx1 nCoV-19 Límite: Humans Idioma: En Revista: Clin Exp Immunol Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / COVID-19 / Vacuna BNT162 / ChAdOx1 nCoV-19 Límite: Humans Idioma: En Revista: Clin Exp Immunol Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido